Navigate to Other Sector


2018: Year end round up of key developments across the Biopharma, MedTech and Healthcare delivery landscape

Robust year for big ticket M&A - Driven by portfolio expansion in rare diseases & next gen therapies

Biosimilars: Landmark year for EMA & FDA approvals - commercial complexities yet to be unraveled

Biotech Funding and Out-Licensing - The IPO Boom & Emerging Markets Coming of Age

Convergence of MedTech, BioPharma & Wellness - Advent of CGMs & Wearables

Tectonic Shifts In The Healthcare Delivery Value Chain & Critical Policy Measures


Connect with Authors at: E-mail

Discussion — No responses

Show Buttons
Hide Buttons